To include your compound in the COVID-19 Resource Center, submit it here.

Fulranumab: Interim Phase II data

Interim data from the 12-week efficacy stage of an ongoing, 104-week, double-blind Phase II trial in 466 patients with moderate to severe osteoarthritic pain of the hip and knee inadequately controlled with current pain therapy showed that 3 mg subcutaneous

Read the full 400 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers